355 related articles for article (PubMed ID: 26929256)
1. Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.
Opatrná S; Pöpperlová A; Lysák D; Fuchsová R; Trefil L; Racek J; Topolčan O
Ther Apher Dial; 2016 Apr; 20(2):149-57. PubMed ID: 26929256
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.
Opatrna S; Lysak D; Trefil L; Parker C; Topley N
Perit Dial Int; 2012; 32(1):37-44. PubMed ID: 22302924
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.
Parikova A; Zweers MM; Struijk DG; Krediet RT
Adv Perit Dial; 2003; 19():186-90. PubMed ID: 14763059
[TBL] [Abstract][Full Text] [Related]
4. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
Fusshoeller A; Plail M; Grabensee B; Plum J
Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
[TBL] [Abstract][Full Text] [Related]
5. Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane.
Moriishi M; Kawanishi H; Watanabe H; Tsuchiya S
Adv Perit Dial; 2005; 21():21-4. PubMed ID: 16686279
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport.
Rodrigues A; Martins M; Santos MJ; Fonseca I; Oliveira JC; Cabrita A; Melo e Castro J; Krediet RT
Adv Perit Dial; 2004; 20():8-12. PubMed ID: 15384786
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.
Posthuma N; ter Wee PM; Donker AJ; Oe PL; Peers EM; Verbrugh HA
Perit Dial Int; 2000; 20 Suppl 2():S106-13. PubMed ID: 10911654
[TBL] [Abstract][Full Text] [Related]
8. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study.
Pajek J; Kveder R; Bren A; Gucek A; Ihan A; Osredkar J; Lindholm B
Perit Dial Int; 2008; 28(1):44-52. PubMed ID: 18178947
[TBL] [Abstract][Full Text] [Related]
9. Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis.
Sanusi AA; Zweers MM; Weening JJ; de Waart DR; Struijk DG; Krediet RT
Perit Dial Int; 2001; 21(5):495-500. PubMed ID: 11757834
[TBL] [Abstract][Full Text] [Related]
10. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
11. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.
Krediet RT
Perit Dial Int; 2001; 21(6):560-7. PubMed ID: 11783764
[TBL] [Abstract][Full Text] [Related]
12. Biocompatibility of a bicarbonate/lactate-buffered PD fluid tested with a double-chamber cell culture system.
Fusshoeller A; Baehr J; Grabensee B; Plum J
Perit Dial Int; 2005; 25(4):387-93. PubMed ID: 16022097
[TBL] [Abstract][Full Text] [Related]
13. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
14. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory factors for hypoalbuminemia in Japanese peritoneal dialysis patients.
Shioya M; Yoshida T; Kasai K; Furuya R; Kato A; Mori N; Matsumoto Y; Kumagai H
Nephrology (Carlton); 2013 Aug; 18(8):539-44. PubMed ID: 23718260
[TBL] [Abstract][Full Text] [Related]
16. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients.
Lopes Barreto D; Coester AM; Noordzij M; Smit W; Struijk DG; Rogers S; de Waart DR; Krediet RT
Nephrol Dial Transplant; 2011 Nov; 26(11):3739-44. PubMed ID: 21498425
[TBL] [Abstract][Full Text] [Related]
17. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?
Martikainen TA; Teppo AM; Grönhagen-Riska C; Ekstrand AV
Perit Dial Int; 2005; 25(5):453-60. PubMed ID: 16178478
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic role of peritoneal CA 125 in peritoneal dialysis patients presenting with acute peritonitis.
Panorchan K; Davenport A
BMC Nephrol; 2014 Sep; 15():149. PubMed ID: 25217152
[TBL] [Abstract][Full Text] [Related]
19. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.
Jones S; Holmes CJ; Krediet RT; Mackenzie R; Faict D; Tranaeus A; Williams JD; Coles GA; Topley N;
Kidney Int; 2001 Apr; 59(4):1529-38. PubMed ID: 11260417
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal follow-up of CA125 in peritoneal effluent.
Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
Kidney Int; 1997 Mar; 51(3):888-93. PubMed ID: 9067926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
